From Clinical Thyroidology® for the Public: Cancer size has been one of the main factors used to decide whether active surveillance is appropriate. It was assumed that larger cancers would be more likely to grow or spread, but this assumption has not been studied in detail. In this study, the researchers evaluated the safety and clinical outcomes of active surveillance in patients with papillary thyroid cancers measuring more than 1.5 cm. Read More…
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.